Clinical trial · Interventional
Residual Disease Evaluation of Resected NSCLC by cirDNA Analysis
Local Undertaking of Resected Non-small Cell Lung Cancer by Generating a Residual Disease Outline Based on Circulating Cell-free DNA
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prognosis of resectable early stages NSCLC might be improved by a better knowledge of post-operative minimal residual disease (MRD). This could be achieved by studying patient with stage I to IIIA completely resected-NSCLC, comparing qualitative and quantitative features of pre- and post-operative circulating cell-free DNA (cirDNA), using MiTest. We assume that the evolution of the parameters of MiTest and relapse rate after surgery are related and expect to prove that normalization of MiTest at one month after surgery is a prognostic factor of reduced relapse at one year.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nsclc | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood sample | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Eligible patients
- interventionNames
- Diagnostic Test: Blood sample
Primary outcomes (1)
- measure
- Recurrence-free survival probability according to MiTest at one year after surgery (RFS1)
- timeFrame
- The year after surgery
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age: 18 years or older * Patients with a resectable NSCLC * Definite stage I to IIIA * Performance status of 0, 1 or 2 * Normal end organ functions * Written and signed informed consent form * Subjects must be covered by public health insurance. Exclusion Criteria: * Any previous systemic neoadjuvant treatment: targeted therapy, chemotherapy, immune checkpoint blockade * Previous radiotherapeutic neoadjuvant treatment * Resection margins R1 and R2 * Non-invasive lung carcinoma * Multiple primary lung cancer. * Previous malignancy during the past 3 years (except non-melanomatous skin cancer) * Preexisting interstitial lung disease * known HIV, active viral B hepatitis or C hepatitis * Patient with any other situation responsible for cirDNA rate increasing (active auto-immune disease, 10 days following blood transfusion) * Patient unable to attend all scheduled visits * Woman of childbearing age without efficient contraception, breastfeeding * Patient with a legal protection measure (guardianship, curatorship) * Vulnerable patient protected by law
References
Publications (0)
Data not yet available